Cargando…

Insulinoma With Concomitant Insulin Antibodies

OBJECTIVE: The coexistence of insulinoma and insulin antibodies is extremely rare. The aim of this novel case report is to inform physicians of the possibility of an insulinoma with concomitant insulin antibodies. METHODS: In this report, we describe a patient with symptomatic hypoglycemia confirmed...

Descripción completa

Detalles Bibliográficos
Autores principales: Iqbal, Anira, Broome, David T., Makin, Vinni, Yogi-Morren, Divya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association of Clinical Endocrinology 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8282515/
https://www.ncbi.nlm.nih.gov/pubmed/34307846
http://dx.doi.org/10.1016/j.aace.2021.01.009
_version_ 1783723029408251904
author Iqbal, Anira
Broome, David T.
Makin, Vinni
Yogi-Morren, Divya
author_facet Iqbal, Anira
Broome, David T.
Makin, Vinni
Yogi-Morren, Divya
author_sort Iqbal, Anira
collection PubMed
description OBJECTIVE: The coexistence of insulinoma and insulin antibodies is extremely rare. The aim of this novel case report is to inform physicians of the possibility of an insulinoma with concomitant insulin antibodies. METHODS: In this report, we describe a patient with symptomatic hypoglycemia confirmed with a 72-hour fast, who was subsequently found to have an insulinoma with concomitant elevation in his immunoglobulin G insulin antibody titer. RESULTS: The patient presented with initial symptoms of diaphoresis, confusion, and disorientation and was found unresponsive by a bystander. He had a fingerstick blood glucose of 36 mg/dL (reference 74-99 mg/dL), without exogenous insulin or sulfonylurea use. His symptoms resolved with administration of glucose. He was subsequently admitted for a 72-hour fast in which he developed neuroglycopenic symptoms 4 hours into the fast with fingerstick glucose of 47 mg/dL and serum glucose of 44 mg/dL (reference 74-99 mg/dL), C-peptide of 10.8 ng/mL (reference 0.5-2.7 ng/mL), insulin level of 106 μIU/mL (reference <25 μIU/mL), and a proinsulin level of 675 pmol/mL (reference <22 pmol/mL). His insulin-to-C-peptide ratio was 0.20, in which a ratio <1 is indicative of an insulinoma. Endoscopic ultrasound demonstrated a 16 x 11 mm biopsy-proven neuroendocrine tumor. He was found to have a high titer insulin antibody titer at 2.4 U/mL (reference <0.4 U/mL), was started on prednisone, and underwent successful radiofrequency ablation. He was able to be successfully tapered off steroids without recurrence. CONCLUSION: The coexistence of insulinoma with insulin antibodies is novel, and to our knowledge, has never been published.
format Online
Article
Text
id pubmed-8282515
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher American Association of Clinical Endocrinology
record_format MEDLINE/PubMed
spelling pubmed-82825152021-07-22 Insulinoma With Concomitant Insulin Antibodies Iqbal, Anira Broome, David T. Makin, Vinni Yogi-Morren, Divya AACE Clin Case Rep Case Report OBJECTIVE: The coexistence of insulinoma and insulin antibodies is extremely rare. The aim of this novel case report is to inform physicians of the possibility of an insulinoma with concomitant insulin antibodies. METHODS: In this report, we describe a patient with symptomatic hypoglycemia confirmed with a 72-hour fast, who was subsequently found to have an insulinoma with concomitant elevation in his immunoglobulin G insulin antibody titer. RESULTS: The patient presented with initial symptoms of diaphoresis, confusion, and disorientation and was found unresponsive by a bystander. He had a fingerstick blood glucose of 36 mg/dL (reference 74-99 mg/dL), without exogenous insulin or sulfonylurea use. His symptoms resolved with administration of glucose. He was subsequently admitted for a 72-hour fast in which he developed neuroglycopenic symptoms 4 hours into the fast with fingerstick glucose of 47 mg/dL and serum glucose of 44 mg/dL (reference 74-99 mg/dL), C-peptide of 10.8 ng/mL (reference 0.5-2.7 ng/mL), insulin level of 106 μIU/mL (reference <25 μIU/mL), and a proinsulin level of 675 pmol/mL (reference <22 pmol/mL). His insulin-to-C-peptide ratio was 0.20, in which a ratio <1 is indicative of an insulinoma. Endoscopic ultrasound demonstrated a 16 x 11 mm biopsy-proven neuroendocrine tumor. He was found to have a high titer insulin antibody titer at 2.4 U/mL (reference <0.4 U/mL), was started on prednisone, and underwent successful radiofrequency ablation. He was able to be successfully tapered off steroids without recurrence. CONCLUSION: The coexistence of insulinoma with insulin antibodies is novel, and to our knowledge, has never been published. American Association of Clinical Endocrinology 2021-02-03 /pmc/articles/PMC8282515/ /pubmed/34307846 http://dx.doi.org/10.1016/j.aace.2021.01.009 Text en © 2021 AACE. Published by Elsevier Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Iqbal, Anira
Broome, David T.
Makin, Vinni
Yogi-Morren, Divya
Insulinoma With Concomitant Insulin Antibodies
title Insulinoma With Concomitant Insulin Antibodies
title_full Insulinoma With Concomitant Insulin Antibodies
title_fullStr Insulinoma With Concomitant Insulin Antibodies
title_full_unstemmed Insulinoma With Concomitant Insulin Antibodies
title_short Insulinoma With Concomitant Insulin Antibodies
title_sort insulinoma with concomitant insulin antibodies
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8282515/
https://www.ncbi.nlm.nih.gov/pubmed/34307846
http://dx.doi.org/10.1016/j.aace.2021.01.009
work_keys_str_mv AT iqbalanira insulinomawithconcomitantinsulinantibodies
AT broomedavidt insulinomawithconcomitantinsulinantibodies
AT makinvinni insulinomawithconcomitantinsulinantibodies
AT yogimorrendivya insulinomawithconcomitantinsulinantibodies